These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

648 related articles for article (PubMed ID: 14534879)

  • 1. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
    Habuchi T; Kamoto T; Hara I; Kawai K; Nakao M; Nonomura N; Kobayashi T; Ogawa O; Kamidono S; Akaza H; Okuyama A; Kato T; Miki T
    Cancer; 2003 Oct; 98(8):1635-42. PubMed ID: 14534879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors.
    Kobayashi T; Kawakita M; Terachi T; Habuchi T; Ogawa O; Kamoto T
    J Surg Oncol; 2006 Dec; 94(7):619-23. PubMed ID: 17111392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients.
    Li J; Yang W; Wu X
    Gynecol Oncol; 2007 Jun; 105(3):769-75. PubMed ID: 17459461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection.
    Beck SD; Foster RS; Bihrle R; Einhorn LH; Donohue JP
    J Clin Oncol; 2005 Sep; 23(25):6149-56. PubMed ID: 16135481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
    Fosså SD; Stenning SP; Gerl A; Horwich A; Clark PI; Wilkinson PM; Jones WG; Williams MV; Oliver RT; Newlands ES; Mead GM; Cullen MH; Kaye SB; Rustin GJ; Cook PA
    Br J Cancer; 1999 Jul; 80(9):1392-9. PubMed ID: 10424741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome.
    Ong TA; Winkler MH; Savage PM; Seckl MJ; Christmas TJ
    BJU Int; 2008 Jul; 102(2):198-202. PubMed ID: 18294302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers.
    Saxman SB; Nichols CR; Foster RS; Messemer JE; Donohue JP; Einhorn LH
    J Urol; 1996 Feb; 155(2):587-9. PubMed ID: 8558665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of tumor markers in newly diagnosed patients with primary central nervous system germ cell tumors.
    Kim A; Ji L; Balmaceda C; Diez B; Kellie SJ; Dunkel IJ; Gardner SL; Sposto R; Finlay JL
    Pediatr Blood Cancer; 2008 Dec; 51(6):768-73. PubMed ID: 18802946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers.
    Albers P; Ganz A; Hannig E; Miersch WD; Müller SC
    J Urol; 2000 Aug; 164(2):381-4. PubMed ID: 10893590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors.
    Beck SD; Patel MI; Sheinfeld J
    J Urol; 2004 Jan; 171(1):168-71. PubMed ID: 14665869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone.
    Coogan CL; Foster RS; Rowland RG; Bihrle R; Smith ER; Einhorn LH; Roth BJ; Donohue JP
    Urology; 1997 Dec; 50(6):957-62. PubMed ID: 9426730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer.
    Spiess PE; Brown GA; Liu P; Tannir NM; Tu SM; Evans JG; Czerniak B; Kamat AM; Pisters LL
    Cancer; 2006 Oct; 107(7):1483-90. PubMed ID: 16944541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?
    Spiess PE; Brown GA; Pisters LL; Liu P; Tu SM; Evans JG; Kamat AM; Black P; Tannir NM
    Cancer; 2006 Oct; 107(7):1503-10. PubMed ID: 16944534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in metastatic nonseminomatous germ cell tumours.
    Hanson PR; Belitsky P; Millard OH; Lannon SG
    Can J Surg; 1993 Dec; 36(6):537-40. PubMed ID: 7504978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
    Beck SD; Foster RS; Bihrle R; Donohue JP
    Urology; 2007 Mar; 69(3):557-9. PubMed ID: 17382165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors.
    Toner GC; Geller NL; Tan C; Nisselbaum J; Bosl GJ
    Cancer Res; 1990 Sep; 50(18):5904-10. PubMed ID: 1697503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of surgery, chemotherapy and irradiation on long term outcome of intracranial malignant non-germinomatous germ cell tumors: results of the German Cooperative Trial MAKEI 89.
    Calaminus G; Bamberg M; Jürgens H; Kortmann RD; Sörensen N; Wiestler OD; Göbel U
    Klin Padiatr; 2004; 216(3):141-9. PubMed ID: 15175958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?
    Gerl A; Lamerz R; Clemm C; Mann K; Hartenstein R; Wilmanns W
    Clin Cancer Res; 1996 Sep; 2(9):1565-70. PubMed ID: 9816334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical treatment of malignant mediastinal nonseminomatous germ cell tumor.
    Kang CH; Kim YT; Jheon SH; Sung SW; Kim JH
    Ann Thorac Surg; 2008 Feb; 85(2):379-84. PubMed ID: 18222229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.